{
    "id": 25255,
    "fullName": "EZH2 Y111D",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EZH2 Y111D lies within the D1 domain of the Ezh2 protein (PMID: 26360609). Y111D has been demonstrated as to occur as a secondary mutation that confers resistance to Ezh2 inhibitors (PMID: 30555699, PMID: 26360609), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                },
                {
                    "id": 16375,
                    "pubMedId": 30555699,
                    "title": "EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30555699"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2146,
        "geneSymbol": "EZH2",
        "terms": [
            "EZH2",
            "ENX-1",
            "ENX1",
            "EZH2b",
            "KMT6",
            "KMT6A",
            "WVS",
            "WVS2"
        ]
    },
    "variant": "Y111D",
    "createDate": "08/18/2016",
    "updateDate": "10/09/2019",
    "referenceTranscriptCoordinates": {
        "id": 171514,
        "transcript": "NM_001203247",
        "gDna": "chr7:g.148832666A>C",
        "cDna": "c.331T>G",
        "protein": "p.Y111D",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7824,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to GSK126 treatment in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26049,
                "profileName": "EZH2 Y111D"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26049,
                "profileName": "EZH2 Y111D"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7816,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous A677G and Y111D mutations were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26052,
                "profileName": "EZH2 Y111D EZH2 A677G"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7815,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EZH2 Y111D conferred resistance to Tazemetostat (EPZ-6438) when occurring in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26052,
                "profileName": "EZH2 Y111D EZH2 A677G"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7817,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EZH2 Y111D conferred resistance to GSK126 when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26052,
                "profileName": "EZH2 Y111D EZH2 A677G"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7818,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous A677G and Y111D mutations were resistant to GSK126 in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26052,
                "profileName": "EZH2 Y111D EZH2 A677G"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7820,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26054,
                "profileName": "EZH2 Y111D EZH2 Y641F"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to GSK126 in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26054,
                "profileName": "EZH2 Y111D EZH2 Y641F"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7826,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26057,
                "profileName": "EZH2 Y111D SMARCB1 inact mut"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 3672,
                "name": "rhabdoid cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26049,
            "profileName": "EZH2 Y111D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26052,
            "profileName": "EZH2 Y111D EZH2 A677G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26054,
            "profileName": "EZH2 Y111D EZH2 Y641F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26055,
            "profileName": "EZH2 Y111D SMARCB1 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26057,
            "profileName": "EZH2 Y111D SMARCB1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171514,
            "transcript": "NM_001203247",
            "gDna": "chr7:g.148832666A>C",
            "cDna": "c.331T>G",
            "protein": "p.Y111D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171516,
            "transcript": "XM_011515884",
            "gDna": "chr7:g.148832666A>C",
            "cDna": "c.331T>G",
            "protein": "p.Y111D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171515,
            "transcript": "NM_004456",
            "gDna": "chr7:g.148832666A>C",
            "cDna": "c.331T>G",
            "protein": "p.Y111D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171517,
            "transcript": "XM_011515889",
            "gDna": "chr7:g.148829815A>C",
            "cDna": "c.331T>G",
            "protein": "p.Y111D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}